 Pyruvate kinase (PK) deficiency rare genetic disease causes chronic hemolytic anemia. currently targeted therapies PK deficiency. Here, describe identification characterization AG-348, allosteric activator PK currently clinical trials treatment PK deficiency. demonstrate AG-348 increase activity wild-type mutant PK enzymes biochemical assays patient red blood cells treated ex vivo. data illustrate potential AG-348 restore glycolytic pathway activity patients PK deficiency ultimately lead clinical benefit.